Arcellx's chief medical officer sells shares worth $498,795

In a recent filing with the Securities and Exchange Commission, Arcellx, Inc. (NASDAQ:ACLX), a biotech company currently valued at $4.28 billion, disclosed that its Chief Medical (TASE:PMCN) Officer, Christopher Heery, sold shares totaling $498,795. The transactions took place on January 3 and January 6, with shares sold at prices ranging from $77.1668 to $79.5481. According to InvestingPro data, the stock has shown remarkable strength with a 38.57% gain over the past six months.

The sales were part of a broker-assisted arrangement to meet tax withholding obligations related to the vesting of restricted stock units. Following these transactions, Heery now holds 32,456 shares of Arcellx's common stock.

Additionally, Heery acquired a significant number of restricted stock units earlier in January, which converted to common stock shares. These acquisitions did not involve any cash transactions.

In other recent news, Arcellx Inc. has been the subject of several analyst reports following the release of promising data from the iMMagine-1 study for anito-cel, a treatment for relapsed or refractory multiple myeloma. Stifel maintained its Buy rating, highlighting the potential of anito-cel in the Multiple Myeloma market. TD Cowen also maintained a Buy rating, praising Arcellx's manufacturing capabilities for anito-cel, which could be a significant advantage in the market for cancer treatments.

BofA Securities increased its price target for Arcellx shares, reiterating a Buy rating based on recent interim pivotal iMMagine-1 data. The analyst highlighted the larger sample size, which supports a competitive profile for anito-cel against Carvykti, a benchmark competitor. Truist Securities, on the other hand, raised its price target while retaining a Buy rating due to Arcellx's robust financial position and promising data for Anito-cel therapy.

Piper Sandler maintained an Overweight rating and raised the price target following Arcellx's third-quarter 2024 earnings report and the upcoming full data release from the iMMagine-1 study at the American Society of Hematology meeting. These recent developments have sparked increased interest in Arcellx, as investors and stakeholders anticipate further insights into the efficacy and safety of anito-cel.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.